Cargando…

MET Expression and Cancer Stem Cell Networks Impact Outcome in High-Grade Serous Ovarian Cancer

Overexpression of the receptor tyrosine kinase MET has been linked to poor survival in several cancer types, and MET has been suggested to interact with stem cell networks. In vitro studies have further suggested a possible benefit of a combined treatment using PARP and MET inhibitors. We used a tis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bååth, Maria, Jönsson, Jenny-Maria, Westbom Fremer, Sofia, Martín de la Fuente, Laura, Tran, Lena, Malander, Susanne, Kannisto, Päivi, Måsbäck, Anna, Honeth, Gabriella, Hedenfalk, Ingrid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155853/ https://www.ncbi.nlm.nih.gov/pubmed/34069138 http://dx.doi.org/10.3390/genes12050742

Ejemplares similares

SOX2 is a promising predictor of relapse and death in advanced stage high-grade serous ovarian cancer patients with residual disease after debulking surgery
por: Bååth, Maria, et al.
Publicado: (2020)

PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma
por: Martin de la Fuente, Laura, et al.
Publicado: (2020)

Molecular Subtyping of Serous Ovarian Tumors Reveals Multiple Connections to Intrinsic Breast Cancer Subtypes
por: Jönsson, Jenny-Maria, et al.
Publicado: (2014)

Homologous Recombination Repair Mechanisms in Serous Endometrial Cancer
por: Jönsson, Jenny-Maria, et al.
Publicado: (2021)

Involvement of Chromatin Remodeling Genes and the Rho GTPases RhoB and CDC42 in Ovarian Clear Cell Carcinoma
por: Arildsen, Nicolai Skovbjerg, et al.
Publicado: (2017)

Detecting TP53 mutations in diagnostic and archival liquid-based Pap samples from ovarian cancer patients using an ultra-sensitive ddPCR method
por: Arildsen, Nicolai Skovbjerg, et al.
Publicado: (2019)

Claudin-4 Expression is Associated With Survival in Ovarian Cancer But Not With Chemotherapy Response
por: Martín de la Fuente, Laura, et al.
Publicado: (2018)

Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer Survival()()
por: Jönsson, Jenny-Maria, et al.
Publicado: (2015)

Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer
por: Sahin, Irem Durmaz, et al.
Publicado: (2019)

Tru-Cut Biopsy in Gynecological Cancer: Adequacy, Accuracy, Safety and Clinical Applicability
por: Asp, Mihaela, et al.
Publicado: (2023)

Age and Referral Route Impact the Access to Diagnosis for Women with Advanced Ovarian Cancer
por: Norbeck, Anna, et al.
Publicado: (2023)

Distinct gene expression profiles in ovarian cancer linked to Lynch syndrome
por: Jönsson, Jenny-Maria, et al.
Publicado: (2014)

The role of computed tomography in the assessment of tumour extent and the risk of residual disease after upfront surgery in advanced ovarian cancer (AOC)
por: Asp, Mihaela, et al.
Publicado: (2022)

A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients
por: Leandersson, Pia, et al.
Publicado: (2020)

Ovarian cancer subtypes and survival in relation to three comprehensive imaging parameters
por: Sartor, Hanna, et al.
Publicado: (2020)

Imaging ovarian cancer – from baseline characteristics to high-risk image factors
por: Sartor, Hanna, et al.
Publicado: (2023)

Regulatory T lymphocyte infiltration in metastatic breast cancer—an independent prognostic factor that changes with tumor progression
por: Stenström, Jenny, et al.
Publicado: (2021)

Low-grade serous epithelial ovarian cancer: a comprehensive review and update for radiologists
por: Amante, Sofia, et al.
Publicado: (2021)

Targeting the Microenvironment in High Grade Serous Ovarian Cancer
por: Nwani, Nkechiyere G., et al.
Publicado: (2018)

The Tumor Microenvironment of High Grade Serous Ovarian Cancer
por: Stack, M. Sharon, et al.
Publicado: (2018)

Cell Origins of High-Grade Serous Ovarian Cancer
por: Kim, Jaeyeon, et al.
Publicado: (2018)

Proteome profiling of low grade serous ovarian cancer
por: zadeh fakhar, Haniyeh Bashi, et al.
Publicado: (2019)

High-grade serous ovarian cancer: the clone wars
por: Salomon-Perzyński, Aleksander, et al.
Publicado: (2017)

The peritoneal tumour microenvironment of high-grade serous ovarian cancer
por: Leinster, D Andrew, et al.
Publicado: (2012)

Principles of dormancy evident in high-grade serous ovarian cancer
por: Shepherd, Trevor G., et al.
Publicado: (2022)

Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers
por: Azzalini, Eros, et al.
Publicado: (2023)

Concurrent Primary Peritoneal Low-Grade Serous Carcinoma and Endometrial High-Grade Serous Carcinoma
por: Lockyer, Megan G., et al.
Publicado: (2015)

High-throughput genomic technology in research and clinical management of breast cancer. Molecular signatures of progression from benign epithelium to metastatic breast cancer
por: Rennstam, Karin, et al.
Publicado: (2006)

Investigating the effect of optimal cytoreduction in the context of platinum sensitivity in high‐grade serous ovarian cancer
por: Cardillo, Nicholas, et al.
Publicado: (2022)

No evidence for PALB2 methylation in high-grade serous ovarian cancer
por: Mikeska, Thomas, et al.
Publicado: (2013)

The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer
por: Yan, Shunfei, et al.
Publicado: (2017)

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
por: Morgan, Robert D., et al.
Publicado: (2018)

First-Line Management of Advanced High-Grade Serous Ovarian Cancer
por: Mahmood, Reem D., et al.
Publicado: (2020)

Prognostic gene expression signature for high-grade serous ovarian cancer
por: Millstein, J., et al.
Publicado: (2020)

Why the dual origins of high grade serous ovarian cancer matter
por: Colvin, Emily K., et al.
Publicado: (2020)

Identification of Novel Fusion Transcripts in High Grade Serous Ovarian Cancer
por: Newtson, Andreea, et al.
Publicado: (2021)

Lipid Alterations in Early-Stage High-Grade Serous Ovarian Cancer
por: Iurova, M. V., et al.
Publicado: (2022)

Role of integrins in the metastatic spread of high-grade serous ovarian cancer
por: Krajnak, Slavomir, et al.
Publicado: (2021)

Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer
por: Chowdhury, Shrabanti, et al.
Publicado: (2023)

IQGAP3 promotes cancer proliferation and metastasis in high-grade serous ovarian cancer
por: Dongol, Samina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_feo39itjvja3pd9phmc20puk1g